GLP-1数据库

每种FDA批准的减重药物的全面循证资料。

Ozempic

(semaglutide)

GLP-1受体激动剂注射剂

适应症: 减重与2型糖尿病

Ozempic is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes, widely used off-label for weigh…

Novo Nordisk

查看完整资料

Wegovy

(semaglutide)

GLP-1受体激动剂注射剂

适应症: 减重

Wegovy is a higher-dose semaglutide injection specifically approved for chronic weight management in adults with obesity…

Novo Nordisk

查看完整资料

Mounjaro

(tirzepatide)

双重GIP/GLP-1受体激动剂注射剂

适应症: 减重与2型糖尿病

Mounjaro is a once-weekly dual GIP/GLP-1 receptor agonist approved for type 2 diabetes, with significant weight loss eff…

Eli Lilly

查看完整资料

Zepbound

(tirzepatide)

双重GIP/GLP-1受体激动剂注射剂

适应症: 减重

Zepbound is a tirzepatide injection specifically approved for chronic weight management, offering the same dual-action m…

Eli Lilly

查看完整资料

Saxenda

(liraglutide)

GLP-1受体激动剂注射剂

适应症: 减重

Saxenda is a daily injectable GLP-1 receptor agonist approved for chronic weight management, an earlier-generation alter…

Novo Nordisk

查看完整资料

Contrave

(naltrexone-bupropion)

其他口服

适应症: 减重

Contrave is an oral combination of naltrexone and bupropion approved for chronic weight management, targeting appetite a…

Currax Pharmaceuticals

查看完整资料